MedTrace Logo

Targeted Therapy of Bronchiolitis Obliterans Syndrome

NCT01307462 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2017-10-04

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well giving fluticasone propionate, azithromycin, and montelukast sodium (FAM) together works in treating patients with bronchiolitis obliterans who previously underwent stem cell transplant. FAM may be an effective treatment for bronchiolitis obliterans

Conditions

  • Bronchiolitis Obliterans

Interventions

DRUG

fluticasone propionate

Given inhaled PO

DRUG

montelukast sodium

Given PO

DRUG

azithromycin

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Stephanie Lee

    lead OTHER

Principal Investigators

  • Stephanie Lee · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

  • Kirsten Williams · National Cancer Institute (NCI)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2014-09-30
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01307462 on ClinicalTrials.gov